Atara Biotherapeutics, Inc. $100 Million At-The-Market Offering

Davis Polk advised the sales agent on the SEC-registered at-the-market offering by Atara Biotherapeutics, Inc. of its common stock for up to an aggregate amount of $100 million.

Based in South San Francisco, California, Atara is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases.

The Davis Polk corporate team included partner Sarah K. Solum and associates Daniel Reichert and Sherry Tan. Partner Rachel D. Kleinberg and associate Danielle Rapaccioli provided tax advice. Partner Pritesh P. Shah and associate Jay Frankel provided intellectual property advice. Associate Matthew R. Silver provided 1940 Act advice. Members of the Davis Polk team are based in the Northern California and New York offices.